文献速递免疫规划卫生政策与健康促进

人乳头瘤病毒疫苗按剂次划分的效果:国家免疫规划数据的更新系统综述

Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs.
PubMed 文献 · Vaccine · 2022-08-12

本更新系统综述检索2007年1月1日至2021年9月29日Medline和Embase数据库,纳入35项观察性研究,评估不同剂次HPV疫苗效果。所有研究均存在中度或严重偏倚风险;三剂次研究28/29项显示显著效果,两剂次19/29项、一剂次18/30项显示显著效果;多数研究三剂次效果估计最高。

要点

  • 35项观察性研究中,三剂次显著效果见于28/29项,两剂次19/29项,一剂次18/30项。
  • 所有研究偏倚风险为中度或严重,严重偏倚可能低估少剂次效果。
  • 按接种年龄分层的研究中,较年轻接种者效果更高,但差异未全部经正式检验。

核心结论

  • HPV疫苗效果的观察性研究存在许多偏倚,需在性活动前接种人群中使用减少偏倚来源的方法进行研究以获得有效效果估计。

研究设计与样本

  • 更新系统文献综述,检索Medline和Embase数据库2007年1月1日至2021年9月29日,纳入35项观察性研究,采用叙述性综合总结数据,并进行选择、信息和混杂偏倚质量评估。

主要发现

  • 35项研究中除一项外均在推荐三剂次接种程序背景下开展;评估国家使用二价HPV疫苗7项、四价HPV疫苗27项、两者均用1项。
  • 9项评估对HPV感染的效果,10项评估生殖器疣,16项评估宫颈异常。
  • 所有研究偏倚风险为中度或严重;评为严重的偏倚可能导致少剂次效果估计偏低。
  • 按接种年龄分层的研究发现较年轻接种年龄效果更高,但差异未全部经正式检验。
  • 多数研究报告三剂次效果估计最高;显著效果见于三剂次28/29项、两剂次19/29项、一剂次18/30项研究。

关键数值与推荐

  • 8项研究评估缓冲期(病例计数滞后期)影响,10项评估两剂次受种者不同剂次间隔。
  • 部分按接种年龄调整或分层的研究发现三剂、两剂和一剂效果相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有研究均评为中度或严重偏倚风险。
  • 评为严重的偏倚可能导致少剂次效果估计偏低。
  • 需在性活动前接种人群中使用减少偏倚来源的方法进行研究以获得有效效果估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human papillomavirus (HPV) vaccines were first licensed as a three-dose series. Two doses are now widely recommended in some age groups; there are data suggesting high efficacy with one dose. We updated a systematic literature review of HPV vaccine effectiveness by number of doses in observational studies. METHODS: We searched Medline and Embase databases from January 1, 2007, through September 29, 2021. Data were extracted and summarized in a narrative synthesis. We also conducted quality assessments for bias due to selection, information, and confounding. RESULTS: Overall, 35 studies were included; all except one were conducted within the context of a recommended three-dose schedule. Evaluations were in countries that used bivalent HPV vaccine (seven), quadrivalent HPV vaccine (27) or both (one). Nine evaluated effectiveness against HPV infection, ten anogenital warts, and 16 cervical abnormalities. All studies were judged to have moderate or serious risk of bias. The biases rated as serious would likely result in lower effectiveness with fewer doses. Investigators attempted to control for or stratify by potentially important variables, such as age at vaccination. Eight studies evaluated impact of buffer periods (lag time) for case counting and 10 evaluated different intervals between doses for two-dose vaccine recipients. Studies that stratified by vaccination age found higher effectiveness with younger age at vaccination, although differences were not all formally tested. Most studies found highest estimates of effectiveness with three doses; significant effectiveness was found among 28/29 studies that evaluated three doses, 19/29 that evaluated two doses, and 18/30 that evaluated one dose. Some studies that adjusted or stratified analyses by age at vaccination found similar effectiveness with three, two and one doses. CONCLUSION: Observational studies of HPV vaccine effectiveness have many biases. Studies examining persons vaccinated prior to sexual activity and using methods to reduce sources of bias are needed for valid effectiveness estimates.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Markowitz LE, Drolet M, Lewis RM, et al. Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs. Vaccine. 2022. PMID: 35965239. doi:10.1016/j.vaccine.2022.06.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。